What is CBL-514?
CBL-514 is a Caliway Biopharmaceuticals small-molecule injectable in global Phase 3 (SUPREME program) for abdominal subcutaneous fat reduction. It is not a peptide and not a GLP-1 drug; company and published materials describe selective adipocyte apoptosis in treated tissue. Investigational only — not FDA-approved. Kybella (deoxycholic acid) remains the only FDA-approved injectable for localized fat, and only for submental fat. Online products labeled “CBL-514 peptide” are not the study drug.
Not a peptide. CBL-514 is a small-molecule investigational injectable. It is not FDA-approved. Anything sold online as "CBL-514 peptide" is not Caliway's study drug. Read the full explainer.
Mechanism of Action
Selective adipocyte apoptosis (injectable lipolysis); local subcutaneous fat reduction — not GLP-1/GIP/glucagon receptor agonism
Target: Adipocytes (localized subcutaneous fat)
Research / educational reference. Educational reference only — not medical advice. CBL-514 is investigational, not FDA-approved, and not a peptide. Community reports are not evidence of efficacy. Anything sold online as CBL-514 is not Caliway's study drug.
Evidence at a glance
Derived · maturity-1.0Human efficacy for an approved label is unproven until regulators act on an NDA. Literature counts are bibliographic, not proof of cosmetic or metabolic outcomes.
Literature maturity
phase_3_candidate 42/100
PubMed hits
7
CT.gov trials
2
Strong-human apps
4
Sample papers
4
Sample articles by era
- 2022-20264
Application grades (curated)
- Human-grade apps4
- Animal / in-vitro0
- Mechanistic0
Does literature support studied applications?
Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.
| Application | Cited evidence | Grade | Community |
|---|---|---|---|
| Abdominal subcutaneous fat reduction | Randomized phase 2/2b trials report subcutaneous volume and scale improvements vs placebo; global phase 3 SUPREME program underway. | Limited human (Phase 2–3 ongoing) | Not available outside clinical trials; not FDA-approved. |
| GLP-1 combination / weight-regain hypothesis | Company-reported rodent work with semaglutide or tirzepatide; Phase 2 combination IND cleared Aug 2026. Not a consumer stack. | Preclinical + early clinical planning | Do not combine with prescription GLP-1s without trial or clinician supervision. |
| Dercum's disease (CBL-514D) | Phase 2a lipoma data published; pain endpoint reported in 2026 company release for CBL-0202DD. | Limited human (orphan path) | Orphan indication; separate formulation from cosmetic abdominal program. |
Pharmacology
Mechanism of action
- •Described mechanism: selective induction of adipocyte apoptosis in injected subcutaneous fat, reducing adipocyte number locally.
- •Not an incretin mimetic — does not replace GLP-1, GIP, or glucagon receptor pharmacology.
Identity & chemistry
Storage & stability
- Lyophilized
- N/A — investigational ready-to-use solution in trials
- Reconstituted
- N/A
Educational estimates. Prefer product labeling and peptide shelf-life tool.
Lab handling posture
Clinical-trial product only. This page is not handling guidance for consumers.
- •CBL-514 is administered in registered trials under investigator supervision.
- •Do not treat research-peptide vial workflows as equivalent.
- •Unapproved online products are not the Caliway investigational drug.
Sample indexed literature
- Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.
Aesthetic surgery journal · 2026 · PMID 42159040
- Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Aesthetic surgery journal · 2025 · PMID 40037659
- Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction.
Aesthetic surgery journal · 2022 · PMID 35709509
- Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study.
JAAD international · 2026 · PMID 41623934
Research Indications
Phase 2/2b RCTs report volume and scale improvements vs placebo; global SUPREME Phase 3 program ongoing (investigational).
Patient- and clinician-reported abdominal fat rating scales improved in phase 2b vs placebo in company-reported analyses.
Small subgroup MRI analyses at EASD 2026 suggested VAT changes; not an approved metabolic indication.
Preclinical combination data with GLP-1 drugs and an IND-cleared phase 2 combo trial; not consumer guidance.
Separate orphan formulation; phase 2a lipoma data published; pain endpoint reported for CBL-0202DD.
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Investigational status | No approved or public self-use schedule | Clinical trials only | Subcutaneous (study sites) |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
CBL-514 is an investigational ready-to-use injectable used in registered clinical trials — not a lyophilized research peptide vial.
- 2
Trial sites prepare and administer study drug under the protocol and investigator supervision.
- 3
PeptIQ does not provide reconstitution, dosing, or self-injection instructions for CBL-514.
- 4
Products sold online as "CBL-514" are not Caliway's investigational candidate and are not FDA-reviewed medicines.
What to Expect
During trial treatment
Multiple sequential injection sessions under protocol; injection-site reactions most common in published studies.
Post-treatment follow-up
Phase 2 programs measured outcomes weeks after the final session (e.g. 4–8 weeks); durability beyond those windows is not established.
With GLP-1 medicines
Only in registered combination trials — not a validated home stack.
If considering online listings
Unapproved products are not Caliway's investigational drug; avoid self-experimentation.
Side Effects & Safety
- Investigational — not FDA-approved for any use
- Injection-site pain, swelling, redness (most common in published phase 2 trials; mostly mild to moderate)
- Transient local reactions; serious events not emphasized in published reports but phase 3 database is incomplete
- Large-volume subcutaneous sessions in trials may not match cosmetic deoxycholic acid visits
- MRI and protocol exclusions apply in studies (e.g. uncontrolled diabetes, coagulation disorders)
- Anything sold online as "CBL-514 peptide" is not the Caliway study drug
CBL-514 is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.
FDA Status & Regulatory Info
CBL-514 is a Caliway Biopharmaceuticals small-molecule injectable in global Phase 3 (SUPREME program) for abdominal subcutaneous fat reduction. It is not a peptide and not a GLP-1 drug; company and published materials describe selective adipocyte apoptosis in treated tissue. Investigational only — not FDA-approved. Kybella (deoxycholic acid) remains the only FDA-approved injectable for localized fat, and only for submental fat. Online products labeled “CBL-514 peptide” are not the study drug.
Frequently Asked Questions
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
What 1,416 users report
Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 32% · Unfavorable overall 8%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 0–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
How repeat users are trending
Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 312 repeat reporters
Share Your Experience
Rate CBL-514 in the PeptIQ app and help the community make informed decisions.
Research References (12)
Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.
- Wiki study page →Source
PubMed
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study
Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025
- Wiki study page →Source
PubMed
Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment
Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026
- Wiki study page →Source
PubMed
Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction
Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022
- Wiki study page →Source
PubMed
Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study
Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026
- Wiki study page →Source
ClinicalTrials.gov
SUPREME-01 (NCT07140939): Phase 3 CBL-514 for abdominal subcutaneous fat
ClinicalTrials.gov. Clinical trial registry. 2026
- Wiki study page →Source
ClinicalTrials.gov
SUPREME-02 (NCT07526974): Phase 3 CBL-514 for abdominal subcutaneous fat
ClinicalTrials.gov. Clinical trial registry. 2026
- Wiki study page →Source
Manufacturer
Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514
Caliway Biopharmaceuticals. Company press release. 2026
- Wiki study page →Source
Manufacturer
Caliway Highlights Global Phase 3 Progress and GLP-1 Combination Strategy (Aug 31, 2026 Investor Conference)
Caliway Biopharmaceuticals. Company press release. 2026
- Wiki study page →Source
Manufacturer
Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514
Caliway Biopharmaceuticals. Company press release. 2026
- Wiki study page →Source
FDA Drug Label
KYBELLA (deoxycholic acid) injection — Prescribing Information
Allergan. FDA Drug Label. 2015
- Wiki study page →Source
Review Article
An experimental drug kills fat cells, rather than shrinking them
Tina Hesman Saey, Science News. Science News. 2026
- Wiki study page →Source
Review Article
CBL-514 injection reduces visceral and subcutaneous fat in trials
News-Medical.net. Conference news summary. 2026
Wiki tools
Observational indexes and compare views for CBL-514.
Often tracked with
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.